Latest Industry Insights
Industry Insight
Mapping 768 Tau Proteoforms Could Advance Alzheimer’s Research
This Q&A with researchers from the Buck Institute and Nautilus Biotechnology reveals how single-molecule proteomics enables unprecedented mapping of tau proteoforms across Alzheimer’s-relevant brain regions.
Industry Insight
Advancing Membrane Protein Research With Cell-Free Expression Systems
At the recent ELRIG Drug Discovery conference, Technology Networks spoke with Dr. Kundan Sharma to learn more about how cell-free expression platforms are transforming membrane protein research.
Industry Insight
Beyond Mutations: Inside Immuto’s Quest To Decode Disease Structure
Immuto Scientific’s structural surfaceomics platform reveals how wild-type proteins adopt disease-specific shapes that drive pathology. Immuto identifies previously invisible drug targets and designs conformation-selective therapies.
Industry Insight
Circular RNA: The Next Frontier for RNA Therapeutics?
Discover how circular RNA and targeted delivery technologies are advancing RNA therapeutics for chronic diseases and vaccines.
Industry Insight
Genomics Testing Needs Structured Data To Succeed
Dr. Heidi Rehm shares insights on how genomics is evolving at the intersection of research and clinical practice. In this Q&A, she highlights the role of AI, global data standards and collaboration in shaping future patient care.
Industry Insight
Advances in Deep Visual Proteomics With Dr. Andreas Mund
Deep Visual Proteomics integrates high-resolution imaging, AI and ultra-sensitive mass spectrometry to map proteins at single-cell resolution while preserving spatial context.
Industry Insight
Unlocking New Frontiers in Immunotherapy Through Collaborative Innovation
In this interview, we explore how single-cell technologies, automation and strategic partnerships are shaping the future of cancer immunotherapy.
Industry Insight
Inside Cambridge’s Collaborative Future: How journey Is Transforming the Lab Space Landscape
In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.
Industry Insight
Have Oral GLP-1 Drugs Reached Their Ceiling?
Are GLP-1 weight loss drugs the best we can do? Learn why some are pursuing alternatives to appetite suppression.
Advertisement